共 181 条
[1]
Kwekkeboom DJ(2008)Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival J Clin Oncol Off J Am Soc Clin Oncol 26 2124-2130
[2]
de Herder WW(2012)Lutetium-labelled peptides for therapy of neuroendocrine tumours Eur J Nucl Med Mol Imaging 39 S103-S112
[3]
Kam BL(2017)Phase 3 trial of 177lu-dotatate for midgut neuroendocrine tumors N Engl J Med 376 125-135
[4]
van Eijck CH(2013)The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours Eur J Nucl Med Mol Imaging 40 800-816
[5]
van Essen M(2011)Peptide receptor radionuclide therapy with Eur J Nucl Med Mol Imaging 38 2125-2135
[6]
Kooij PP(2015)Lu-DOTATATE: the IEO phase I-II study BJR Case Rep 1 20150177-S19
[7]
Kam BLR(2010)177Lu-Dotatate therapy for the treatment of metastatic neuroendocrine tumours in a patient on haemodialysis—dosimetric considerations Int J Radiat Oncol Biol Phys 76 S10-1899
[8]
Teunissen JJM(2008)Use of normal tissue complication probability models in the clinic J Nucl Med Off Publ Soc Nucl Med 49 1884-41
[9]
Krenning EP(2013)MIRD pamphlet no. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy J Nucl Med Off Publ Soc Nucl Med 54 33-122
[10]
de Herder WW(1991)Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment Int J Radiat Oncol Biol Phys 21 109-227